The Use of Autologous Blood Clot in Management of Chronic Wounds in Specialized Nursing Facility (SNF)

Background: The RD1 product (RedDress Ltd.) which was cleared by FDA in July 2018, for creating autologous blood clots for management of cutaneous wounds, is investigated in a SNF setting as part of a post market surveillance study.

Tools and method: The post marketing study was approved by IRB. The study is conducted in SunnyView Nursing and Rehabilitation Center Butler PA, a 240 beds facility with dedicated wound care team. Wounds are treated weekly for up to 16 weeks with the RD1

Results: Total of 13 subjects enrolled to date, of which: 5 PUs, 3 VLUs, 4 Skin Tears (ST), 1 DFU. 5 could not complete treatment: 3 early discharge, 1 passed away, 1 did not agree to blood draw. Out of 8 subjects, 5 completed treatment with 4 achieving complete healing and 3 are ongoing. Average procedure time was 22 minutes.

Conclusion: The use of RD1 in a SNF setting is investigated and shows promising results, with healing consistent to the rates reported in previous studies. The potential of bringing an affordable cost saving advanced treatment to SNF may allow SNF to get to healing rates as seen in advanced wound clinics.